Four weekly infusions of the novel human apolipoprotein A1 (apoA-I) CSL112 did not significantly reduce 90-day incidence of cardiovascular (CV) death, myocardial infarction (MI) or stroke compared to placebo, in acute myocardial infarction (AMI) patients with multivessel disease and additional cardiovascular risk factors, according to data from the AEGIS-II Trial.